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osting by EAbstract Molecular signaling of messages emanating from cellular membranes through receptor
tyrosine kinases (RTKs) is a major mechanism for intercellular communication and transduction
during development and metabolism, as well as in disease-associated processes. The phosphoryla-
tion status and signaling activity of RTKs are determined by a dynamic equilibrium of the activity
of both RTKs and protein tyrosine phosphatases (PTPs). RTKs are essentially a class of cell-surface
receptors for growth factors and other extracellular ligands, the most conspicuous perhaps are
members of the vascular endothelial growth factor (VEGF) gene family, which plays a fundamental
role in the growth and differentiation of vascular, as well as lymphatic endothelial cells. In partic-
ular, VEGF is a major regulator of normal (physiologic) and abnormal (cancerous) angiogenesis,
including that associated with tumors and cancer. Blockers/inhibitors and regulators of RTKs
are indeed promising cancer interventions, their speciﬁc mechanisms are yet to be unraveled. In this
cutting-edge synopsis, I elaborate on breakthroughs/advances and current concepts of RTK regu-
lation, further shedding light on exploring the role of potential regulators, particularly the RTKo.uk
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104 J.J. Haddadinhibitor Semaxanib, and the mechanisms associated with tumorigenesis in an effort to understand
a potentially alleviating pharmacologic therapeutic intervention. This survey also tackles the loop-
holes and shortcomings of the aforementioned inhibitory role of Semaxanib, especially its inefﬁcacy
and ultimate discontinuation of relevant clinical trials.
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The ramiﬁcations of anti-angiogenesis approach, via the regu-
lation of speciﬁc kinases and their receptors, as a targeted ther-
apy in many types of cancer are indeed perplexing. In my
search for small molecules that have been in clinical trials
and/or in markets targeting receptor kinases whose biochemis-
try is tailored for the support of angiogenesis, a hallmark pro-
cess in cancer evolution and propagation, I witnessed a myriad
of developing drugs, including Semaxanib and bioengineered
monoclonal antibodies, commonly dubbed as MABs. It is
not my intention though to hijack authoritative references in-
volved with anti-angiogenesis control in just one or two mole-
cules that are or have been potentially promising drugs for
cancer therapeutics. Furthermore, I do not intend under any
circumstance to fringe upon any patented rights or legal issues
pertaining to discussed drugs, rather I endeavor to present
what is common in the literature around us as thematically
and objectively as I am possibly capable of and to the best
of my ability.
I will present in this synopsis an overview of receptor tyrosine
kinase regulation and involvement in reinforcing the mechanics
of the process of angiogenesis, commonly involved with the evo-
lution of many types of cancer as I have and will be indicating
throughout. I then touch base with the chronological design
and development of the so called SU-5416, or Semazanib, walk-
ing the reader through its pharmacokinetics and undertaken
clinical trials, emphasizing the ups and downs, the efﬁcacy and
loopholes, and ﬁnally its discontinuation. From that I buildon the recent advances in therapeutic approaches replacing the
ﬁrst generation ofmolecules targeting receptor tyrosine kinases in-
volved in vascular endothelial growth factor-mediated angiogene-
sis and the ensuing development of cancer.One such example I will
stress on is the second generation of MABs, particularly pointing
ﬁnger to a very promising anti-angiogenesis drug, I emphatically
meant bevacizumab (Avastin). Lessons learned throughout are
a take-homemessage: ‘‘Today’s drugmarket is inundatedwith spe-
ciﬁc and rather non-speciﬁc, or more accurately non-efﬁcacious
molecules, yet what is seemingly promising may not be as such in
theupcoming years.’’ Burgeoning research that is continuing apace
is pioneering and challenging at the same time in and of itself to try
and identify not only potential targets but also effective drugs for
cancer treatment and prevention.
2. Receptor tyrosine kinase regulation – an overview
Tyrosine kinases (TKs) are a subclass of speciﬁc and selective
protein kinases that can transfer a phosphate group from ATP
to another protein; conspicuously, they function as an ‘‘on’’ or
‘‘off’’ switch in many cellular/molecular functions (Hanks
et al., 1988). The phosphate group is usually attached to the
amino acid tyrosine on the protein. Moreover, TKs are consid-
ered a subgroup of the larger class of protein kinases that at-
tach phosphate groups to other amino acids (particularly,
serine and threonine) (Radha et al., 1996).
Phosphorylation of proteins via the action of kinases is
understandably an important mechanism in intracellular signal
transduction and in regulating cellular activity, such as the
Figure 1 The molecular structure of tyrosine kinase (TK).
Anti-angiogenesis and receptor tyrosine kinase regulation 105ensuing cell cycle and cell division. Protein kinases can become
mutated thus lock in the ‘‘on’’ position, for instance, and there-
fore cause unregulated cellular growth, one of the hallmarks of
imposing and developing cancer (Ruetten and Thiemermann,
1997; Schaller et al., 1992; Dengjel et al., 2009). Therefore, it
is reasonable to deduce that kinase inhibitors and regulators
are often effective in cancer treatment. On the other hand,
most tyrosine kinases have an associated protein tyrosine
phosphatase, which removes the phosphate group, and hence
acts as an internal regulator (Hanks et al., 1988).
Receptor tyrosine kinases (RTKs) are the high-afﬁnity cell-
surface receptors for many polypeptide growth factors,
cytokines, and hormones. Effectively, of the 90 unique tyrosine
kinase genes identiﬁed in the human genome, approximately
58 encode receptor tyrosine kinase proteins. Receptor tyrosine
kinases have been shown not only to be key regulators of nor-
mal cellular processes, but also to have a critical role in the
development and progression of many types of cancer, as
has been earlier alluded to (Fig. 1) (Hanks et al., 1988; Radha
et al., 1996; Ruetten and Thiemermann, 1997).
3. Receptor tyrosine kinase families – a synopsis
The tyrosine kinases are divided into two main families: the
transmembrane receptor-linked kinases and those that are
cytoplasmic proteins. Approximately 2000 kinases are known,
and more than 90 protein tyrosine kinases (PTKs) have been
found separately and in clusters within the human genome
(Dengjel et al., 2009). They are divided into two classes: recep-
tor and non-receptor PTKs. Currently, 58 RTKs are well
known, grouped into 20 subfamilies. They play pivotal roles
in diverse cellular activities including growth, differentiation,
metabolism, adhesion, motility, and death (apoptosis) (Hanks
et al., 1988; Radha et al., 1996; Ruetten and Thiemermann,
1997; Schaller et al., 1992; Dengjel et al., 2009).
Structurally, RTKs are composed of an extracellular do-
main, which is able to bind a speciﬁc ligand, a transmembrane
domain, and an intracellular catalytic domain, which is able to
bind and phosphorylate the selected substrates. Binding of a
ligand to the extracellular region causes a series of structural
(morphologic) rearrangements in the RTK that lead to its
enzymatic activation. In particular, movement of some parts
of the kinase domain gives free access to ATP and the sub-
strate to the active site. This triggers a cascade of eventsthrough phosphorylation of intracellular proteins that ulti-
mately transduce the extracellular signal, causing changes in
the proﬁle of gene expression (Dengjel et al., 2009; Blanke
et al., 2008; le Coutre et al., 2008).
Many RTKs are involved in oncogenesis, either by gene
mutation, or chromosome translocation, or simply by over-
expression. In every case, the result is a hyperactive kinase,
which confers an aberrant, ligand-independent, non-regulated
growth stimulus to the cancer cells. In humans, particularly,
there are 32 cytoplasmic PTKs. The ﬁrst non-receptor tyrosine
kinase identiﬁed was the v-src oncogenic protein (Fig. 2)
(Blanke et al., 2008; le Coutre et al., 2008; Kuwai et al., 2008).
Most animal cells contain one or more members of the Src
family of tyrosine kinases. For instance, a chicken sarcoma virus
was found to carry mutated versions of the normal cellular Src
gene. The mutated v-src gene has lost the normal built-in inhibi-
tion of enzyme activity that is characteristic of cellular Src (c-src)
genes. Src family members have been found to regulate many
cellular processes (Wiley and Burke, 2001; Rinker et al., 2008;
Silvennoinen et al., 1997; Bhise et al., 2004). For example, the
T-cell antigen receptor leads to intracellular signaling by the
activation of Lck and Fyn, two proteins that are structurally
similar to Src (Gunby et al., 2007; Kris et al., 2003; Sordella
et al., 2004).
In upcoming paragraphs, the author is inclined to point the
attention of the reader to RTK-related families and subgroups,
tailored particularly for VEGF. Although related families such
as ﬁbroblast growth factor receptors (FGFRs) and RET, a
receptor for members of the glial cell line-derived neurotrophic
factor (GDNF) family of extracellular signaling molecules or li-
gands (GFLs) have been identiﬁed, I will speciﬁcally highlight
and emphasize the VEGF/RTKs connection relevant to
Semaxanib. There are excellent references the readers may want
to consult with pertaining to the aforementioned families of
FGFR and RET (Okamoto, 2010; Druker et al., 2001; Joensuu
et al., 2001; Robinson et al., 2001; Zwick et al., 2001; Pawson,
1995; Ornitz and Itoh, 2001; Duchesne and Tissot, 2006; Coutts
and Gallagher, 1995; Sleeman and Fraser, 2001; Robinson and
Stringer, 2001; Myers and Eng, 1995; Baloh and Enomoto,
2000; Airaksinen et al., 1999; Arighi et al., 2005).
3.1. Vascular endothelial growth factor receptor (VEGFR)
family
Vascular endothelial growth factor (VEGF) is one of the main
activators and inducers of endothelial cell proliferation and the
permeability of blood vessels (Robinson and Stringer, 2001).
At least two RTKs bind to VEGF at the cell surface: VEG-
FR-1 (termed Flt-1) and VEGFR-2 (termed KDR/Flk-1).
The VEGF receptors have an extracellular portion consisting
of seven immunoglobulin (Ig)-like domains so, like FGFRs,
they belong to the immunoglobulin superfamily. They also
possess a single transmembrane spanning region and an intra-
cellular portion containing a split tyrosine kinase domain.
Moreover, VEGF-A speciﬁcally binds to VEGFR-1 (Flt-1)
and VEGFR-2 (KDR/Flk-1) receptors.
On the functional side, while VEGFR-2 appears to mediate
almost all of the pervasive, well known cellular responses to
VEGF, the function of VEGFR-1 is less well deﬁned, although
it is thought to modulate VEGFR-2 signaling. Another func-
tion of VEGFR-1 may be to act as a dummy/decoy receptor,
sequestering VEGF from VEGFR-2 binding (this appears to
Figure 2 The major families of RTKs. Receptor tyrosine kinases span the membrane of the cell and have a hormone receptor on the
outside and a tyrosine kinase portion on the inside. There are several subclasses of these receptors as shown here.
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ing embryo). Relatively recently, another receptor has been
discovered (termed VEGFR-3); however, what is actually
known is that VEGF-A is not a ligand for this receptor. Fur-
thermore, VEGFR-3 seems to mediate lymph angiogenesis in
response to VEGF-C and VEGF-D (Robinson and Stringer,
2001).
3.2. Receptor tyrosine kinases (RTKs)
These receptors are transmembrane proteins that span the
plasma membrane just once. Almost 58 different RTKs are
known in humans. Some of the ligands that can trigger
RTKs are: (i) insulin; (ii) insulin-like growth factor-1
(IGF-1); (iii) vascular endothelial growth factor (VEGF); (iv)
platelet-derived growth factor (PDGF); (v) epidermal growth
factor (EGF); and (vi) ﬁbroblast growth factor (FGF)
(Fig. 2). (Notably, a mutation in one of these receptors causes
typical achondroplasia – the most common type of dwarf-
ism (Hanks et al., 1988; Radha et al., 1996; Ruetten and
Thiemermann, 1997; Schaller et al., 1992; Dengjel et al., 2009).)
Technically, binding of the ligand to two adjacent receptors
forms an active homodimer. This activated dimer is essentially
a tyrosine kinase, an enzyme that attaches phosphate groups to
certain tyrosine (Tyr) residues – ﬁrst on itself, then on other
proteins converting them into an active state. Many of these
other proteins are also tyrosine kinases (the human genome en-
codes almost 90 different tyrosine kinases) and in this way a
cascade of expanding phosphorylation occurs within the cyto-
sol. Furthermore, some of these cytosolic tyrosine kinases act
directly on gene transcription by barging onto the nucleus
and transferring their phosphate to transcription factors thus
activating them (Hanks et al., 1988). To cite an example, the
cytosol of B cells contains the Btk (Bruton’s tyrosine kinase),
which is essential to turning on appropriate gene expression
when a B cell encounters a speciﬁc antigen. Inheritedmutations in the gene encoding Btk have been reported to
cause X-linked agammaglobulinemia in males. This mutation
can lead to downregulation of the manufacturing of antibodies
and, therefore, may induce recurrent bacterial infections unless
the afﬂicted individuals are given periodic injections of im-
mune globulin (IG). Moreover, others act indirectly through
the production of second messengers (Hanks et al., 1988).
At the regulatory level, it is apparent that a cell must also be
able to stop responding to a signal. For growth factor recep-
tors, failure to do so could lead to uncontrolled mitosis, or
probably cancer. For the RTKs, this is done by quickly engulf-
ing and destroying the ligand-receptor complex by receptor-
mediated endocytosis (Dengjel et al., 2009; Wiley and Burke,
2001). One might expect that anything that leads to the inap-
propriate expression of receptors that trigger cell division
could lead to uncontrolled cell division and cancer. In fact,
the gene encoding PDGF, which is termed SIS, is a proto-
oncogene, and mutated versions purportedly participate in
making the cell cancerous. Furthermore, the genes encoding
receptors for EGF are allegedly considered proto-oncogenes
and are expressed at abnormally high levels in several human
cancers. Two monoclonal antibodies that target these recep-
tors recently identiﬁed are: Trastuzumab (Herceptin) that
inactivates HER2 (human epidermal growth factor receptor
2) and Cetuximab (Erbitux) that inactivates HER1; both reg-
ulators show astounding promise against breast cancer (Kuwai
et al., 2008; Wiley and Burke, 2001; Rinker et al., 2008; Silven-
noinen et al., 1997; Bhise et al., 2004).
In parallel, two tyrosine kinase inhibitors, termed Geﬁtinib
(Iressa) and Erlotinib (Tarceva), have recently been shown
to block the action of the EGF receptors on the cells of certain
lung cancers and have shown some promise against these can-
cers (Hanks et al., 1988; Radha et al., 1996). Mutant versions
of some of the ‘‘second-order’’ kinases are also associated with
cancer: The oncogene SRC encodes a mutated version of a
normal tyrosine kinase associated with the inner face of the
Figure 3 The molecular structure of Semaxanib, SU-5416.
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produced by the Philadelphia chromosome activates constitu-
tively the cytosolic tyrosine kinase ABL that normally would
be activated only when the cell is stimulated by a growth factor
(e.g., PDGF). The result is the debilitating chronic myeloge-
nous leukemia (CML) (Rinker et al., 2008; Silvennoinen
et al., 1997; Bhise et al., 2004; Gunby et al., 2007; Kris et al.,
2003; Sordella et al., 2004). Another promising treatment is
Imatinib mesylate (Gleevec, also known STI571). This mole-
cule ﬁts into the active site of the ABL protein thus preventing
ATP from binding there. Without ATP as a phosphate donor,
the ABL protein cannot phosphorylate its substrate(s) (Blanke
et al., 2008).
Furthermore, the RAF kinase has been reported to partici-
pate in a signaling pathway that links RTKs to gene activation.
Binding of a ligand to the RTK activates an intracellular mole-
cule called RAS, which then activates RAF. In mammals, this
pathway promotes cellular mitosis. Excessive activities of the
RAS gene ormutations inRAS and/or RAF are associated with
many types of cancer, so RAS and RAF are considered proto-
oncogenes. Almost 15%of all human tumors contain amutated
RAF, and 66% of melanomas – a highly malignant skin cancer
ofmelanocytes – contain amutatedRAF (calledBRAF) (Rinker
et al., 2008; Silvennoinen et al., 1997; Bhise et al., 2004; Gunby
et al., 2007; Kris et al., 2003; Sordella et al., 2004).
Given the wealth of the aforementioned, it is not surprising
to indicate that in order to reduce enzyme activity, inhibitor
molecules should tightly bind to the enzymes. Reducing en-
zyme activity can disable a pathogen or correct an incorrectly
function system; as such, many enzyme inhibitors are devel-
oped to be used as drugs for the general public. Gastrointesti-
nal stromal tumors (GIST), for example, are mesenchymal
tumors that affect the gastrointestinal tract (Hanks et al.,
1988; Radha et al., 1996; Ruetten and Thiemermann, 1997;
Schaller et al., 1992; Dengjel et al., 2009). Treatment options
have been limited. However Imatinib, as an inhibitor to the
malfunctioning enzyme, can be effective. If Imatinib does not
work, patients with advanced chronic myelogenous leukemia
can use Nilotinib, another inhibitor to the malfunction enzyme
that allegedly causes the leukemia. This inhibitor is a highly
selective Bcr–Abl tyrosine kinase inhibitor (Blanke et al.,
2008). Sunitinib, on the other hand, is an oral tyrosine kinase
inhibitor that acts upon VEGFR, platelet-derived growth fac-
tor receptor (PDGFR), stem cell factor receptor (SCFR), and
colony-stimulating factor (CSF)-1 receptor. Furthermore, Gef-
itinib inhibits the tyrosine kinase domain of epidermal growth
factor receptor (EGFR). Kinase inhibitors can also mediate;
paracrine signaling, for instance, mediates the response to
EGFR kinase inhibitors. Paracrine activates epidermal growth
factor receptor in endothelial cells of the tumor to do this
(Hanks et al., 1988; Dengjel et al., 2009).
4. Chronological assessment of receptor tyrosine kinase
inhibition – the case of Semaxanib (SU-5416)
Semaxanib (also known as semaxinib or SU-5416) is a drug
initially intended for the treatment of cancer. It was still at
an experimental stage and as such has not yet received a license
for use on human patients (except, however unsuccessfully, in
the setting of a clinical trial). Semaxanib was considered a po-
tent and selective synthetic inhibitor of the Flk-1/KDR VEGF
receptor tyrosine kinase; the inhibitor targets the VEGFpathway, and both in vivo and in vitro studies have demon-
strated anti-angiogenic potential (O’Donnell et al., 2005;
Lockhart et al., 2006; Hoff, 2006).
SU-5416 {3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indo-
lin-2-one} (Fig. 3), the Sugen (Pharmacia) Semaxanib com-
pound identiﬁed from a large screen of potential inhibitors
of phosphotyrosine kinases, is considered a potent and selec-
tive inhibitor of the kinase-insert domain-containing receptor
(KDR)/Flk-1 RTK (Haluska and Adjei, 2001; Mendel et al.,
2000a), a high-afﬁnity receptor for the VEGF family of growth
factors. SU-5416 has been developed as an anti-angiogenic
compound for the potential therapeutic treatment of solid tu-
mors mediated by suppression of metastasis and angiogenesis.
Subsequently, Sugen Inc. (USA) and Taiho Pharmaceutical
Co., Ltd. have agreed to pursue a joint development program
for Sugen’s angiogenesis inhibitors.
As of July 1998, Taiho was providing a proportion of the
funding for the development of Sugen’s angiogenesis inhibitors
and was to receive marketing rights in Japan. In August 1998,
a patent, which covered the composition of inhibitory com-
pounds for the treatment of a variety of diseases (including
cancer), was issued to Sugen covering a family of compounds,
including SU-5416 (Haluska and Adjei, 2001; Mendel et al.,
2000a). Phase I trials with SU-5416 began at UCLA School
of Medicine in September 1997 to assess safety and dosage
range in approximately 30 patients with advanced malignan-
cies (Hannah, 1997; Rosen et al., 1998). In May 1998, interim
results of the phase I study were presented at the 34th ASCO
meeting in Los Angeles, CA, indicating tolerance at a dose
range of 4.4–65 mg/m2.
In June 1998, plans for two additional trials were re-
ported: The ﬁrst was a phase I/II investigation conducted
at the Cancer Research Campaign Center for Cancer Thera-
peutics at the Institute for Cancer Research and the Royal
Marsden Hospital in London, UK, to assess leakage of tu-
mor blood vessels as a biological marker for the angiogenic
process, in addition to monitoring safety and pharmacoki-
netic parameters for SU-5416; the second study which was
initiated at the Arizona Cancer Center, assessed alternative
dose regimen for the compound in patients with advanced
malignancies, including those with multiple tumors (Hannah,
1997; Rosen et al., 1998). Complete analysis of the results
was reported at the Biologic Principles for the Therapy of
Human Colon Cancer meeting in November 1998. Final
experimental results of the phase I trial for SU-5614 were
presented in May 1999 at the 35th ASCO meeting in Atlanta,
GA, which showed that this drug was well tolerated for
chronic administration at biologically active dose levels with
the demonstration of clinical activity in certain tumor types
(Mendel et al., 2000a; Hannah, 1997; Rosen et al., 1998).
By January 1999, phase III lung cancer studies were
planned for the ﬁrst half of 1999. In June 1999, the FDA
Figure 4 The growth factor receptor interactions involving
RTKs and MAPK signaling pathways.
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pound in colorectal and NSCLC. The trials were to compare
Semaxanib against standard chemotherapy regimens in pa-
tients who had not yet received any chemotherapy. The
primary endpoint of the trial was survival, with secondary end-
points of time-to-disease progression and objective response
rates (Hannah, 1997). Furthermore, in April 2000, data from
a phase I/II open-label, dose-escalating study of SU-5416 were
reported at the 91st AACR meeting in San Francisco, CA. As
a follow-up, pharmacokinetic data from four phase I and
three phase II investigations were presented at the NCI-
EORTC-AACR 11th symposium on New Drugs in Cancer
in Amsterdam, The Netherlands. In May 2001, phase II data
for SU-5416 in patients with metastatic melanoma were
reported at the 37th ASCO meeting in San Francisco, CA,
when the occurrence of one stable disease and one mixed
response, coupled with preliminary data on tumor vascular
perfusion has supported further investigation of this drug in
this patient population (Haluska and Adjei, 2001; Mendel
et al., 2000a; Hannah, 1997; Rosen et al., 1998).
5. Molecular mechanisms of receptor tyrosine kinase regulation
and the Semaxanib connection
As indicated, molecular signaling of messages emanating from
cell membranes through RTKs is a major mechanism for inter-
cellular communication during development and metabolism,
as well as in disease-associated processes (Fig. 4) (Bilder and
Rojas, 1996; Shawver et al., 1997; Strawn and Shawver, 1998;
King et al., 1993; McMahon et al., 1998; Traxler, 1998; Sun
et al., 2000; Sun andMcMahon, 2000; Teicher, 2000). The phos-
phorylation status and signaling activity of RTKs are deter-
mined by a dynamic equilibrium of the activity of both RTKs
and protein tyrosine phosphatases (PTPs) (Spivak et al., 1992;
Petrone and Sap, 2000; Yao et al., 1998). I have reported earlier
on thatRTKs are a class of cell-surface receptors for growth fac-
tors and other extracellular ligands, the most conspicuous per-
haps are members of the VEGF gene family, which plays a
fundamental role in the growth and differentiation of vascular
as well as lymphatic endothelial cells (major requirement for
angiogenesis). This family includes several members including
VEGF, placenta growth factor (PlGF), VEGF-B, VEGF-C,
VEGF-D and two VEGF-like proteins encoded by parapoxvi-
rus orf virus. In particular, VEGF, referred to also as VEGF-
A, is a major regulator of normal and abnormal angiogenesis,
including those associated with tumors (Oliver et al., 1995).
Angiogenesis is a mechanistic developmental process, which
involves the generation and growth of new blood vessels (neo-
vascularization) from pre-existing vasculature (Vlodavsky
et al., 1990; Klagbrun and D’Amore, 1991; Pili et al., 2001).
The angiogenic process is deﬁned by the activation of quiescent
endothelial cells in pre-existing blood vessels followed by the
growth andmigration of the aforementioned cells leading to dis-
solution of the vessel basement membrane. The migration and
proliferation of endothelial cells then form new capillary lumina
and loops that lead to the creation of a new basementmembrane
and maturation of microvessels. In physiological conditions,
angiogenesis has been regarded as tightly controlled process that
requires the balance of the anti-angiogenic and pro-angiogenic
factors. However, angiogenesis may well play a detrimental role
in the growth of solid tumors and their invasion and metastasis
in pathophysiological conditions (see the diagrammaticrepresentation; Fig. 1) (Oikawa, 1995; Le et al., 1993; Plate,
1996; Ono et al., 1997).
The growth of tumor cells is dependent on growth factors
derived from tumor (autocrine stimulation) or microenviron-
ment (paracrine stimulation). PDGF and FGF, for instance,
are secreted from tumor cells and neighboring stromal and
normal tissues (brain, liver, lung, bone, etc.) thereby leading
to enhanced growth and survival. VEGF, FGF and PDGF
stimulate the branching, extension and survival of endothelial
cells resulting in the formation of new blood vessels during the
progression of tumor angiogenesis (Neufeld et al., 1999).
Moreover, VEGF-A and its related family members VEGF-
B and VEGF-C, which elicit a pronounced angiogenic re-
sponse, are mitogens for vascular endothelial cells derived
from arteries, veins and lymphatics, and are involved in a vari-
ety of physiological and pathological neo-vascularization pro-
cess, including wound healing, coronary and peripheral
arterial collateral development (Ware and Simon, 1997), pri-
mary and secondary tumors (Folkman, 1995), retinopathy
(Aiello et al., 1997, 1994), rheumatoid arthritis, psoriasis and
other bullous skin diseases (Brown et al., 1995).
VEGFs are secreted and expressed by tumor cells and sur-
rounding stromal tissue in response to hypoxia. These growth
factors transduce their biological activities following binding
to RTKs (Dumas, 2001; McMahon, 2000). VEGF-A, perhaps
the most intensively studied growth factor family member,
exerts its biological effects via interaction with three
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Flt-1) (Hanks et al., 1988; Dengjel et al., 2009; Fong et al.,
1995; Seetharam et al., 1995; Sun and McMahon, 2000),
VEGF-R2 (fetal liver tyrosine kinase 1/kinase insert
domain-containing receptor; Flk-1/KDR) (Quinn et al., 1993;
Gerber et al., 1998), and neurophilin-1 (Soker et al., 1998).
Both Flt-1 and Flk-1/KDR have seven immunoglobulin
(Ig)-like domains in the extracellular domain, a single trans-
membrane region, and a tyrosine kinase domain, which is inter-
rupted by a kinase-insert domain.
There is compelling evidence that Flk-1/KDR receptor is the
key signaling receptor involved in mediating the initiation and
propagation of embryonic vasculogenesis as well as angiogene-
sis during adult life (Strawn et al., 1996; Shawver, 1999), since
knockout investigations revealed embryonic lethality associated
with gross abnormality of vascularization (Shalaby et al., 1995).
Furthermore, Flk-1/KDR is indispensable for tumor angiogen-
esis and, hence, plays a pivotal role in tumor growth, invasion
and metastasis, since inhibition of Flk-1/KDR signaling by a
dominant negative construct effectively suppressed glioblas-
toma growth in vivo (Millauer et al., 1994). Flt-1, on the other
hand, functions, at least in some circumstances, as a decoy
receptor with high-afﬁnity to recombinant human VEGF,
whereas neurophilin-1 acts by potentiating VEGF binding to
Flk-1/KDR (Keyt et al., 1996) (see the diagrammatic represen-
tation; Fig. 5).
During the past decade, chemically diverse small-molecule
protein kinase inhibitors have been discovered to be of
potential therapeutic value for the treatment of various
human diseases, such as retinopathy, atherosclerosis and
solid tumor growth (Harris, 1998; Raymond, 1998; Oo and
Baumgartner, 1998; Stover et al., 1999; Traxler and Furet,
1999; Arasteh and Hannah, 2000; Vajkoczy et al., 2000;
Ellis et al., 2000; Puduvalli and Sawaya, 2000; Liekens
et al., 2001; Brostjan et al., 2000; Mitsuyasu, 2000; Ryan
and Wilding, 2000; Deplanque and Harris, 2000). SU-5416
(Semaxanib) was found to be a potent and selective inhibitor
of Flk-1/KDR receptor when tested using both kinase
and cellular assays. In particular, it selectively inhibits
VEGF-dependent mitogenesis and migration of human
endothelial cells without inhibiting the growth of a variety
of tumor cells in tissue culture systems. However, SU-5416
signiﬁcantly inhibited the growth of many tumor cell lines
when grown as subcutaneous xenografts in mice, suggesting
the involvement of a paracrine pathway consistent with the
angiogenesis mechanism.
Furthermore, SU-5416 altered tumor vascular density and
vascular leakage after tumor implantation, and induced the
regression of established tumors and apoptosis of endothelial
cells in a model of colon metastasis. SU-5416 exhibited a novel
biologic activity in patients with AIDS-related Kaposi’s sar-
coma, a disease characterized by small tumors on the skin that
are fueled by angiogenesis. This makes SU-6416 a strategically
well positioned drug with promises for future applications in
cancer therapy, provided its safety and efﬁcacy persists in clin-
ical trials (Vacca et al., 2000; Philip, 2000; Liekens et al., 2001).
It is worth mentioning that albeit the initial trials for Semaxa-
nib were relatively successful, further trials especially phase III
trials, were not – this prompted the withdrawal of any further
investigation, especially when a new generation of RTK inhib-
itors have been injected into the market.6. Semaxanib synthesis and SAR
Recent advances in the understanding of the signaling mecha-
nisms involved in neo-vascularization, which suggested that
intervening against certain growth factor receptors and their
associated signaling pathways may provide a promising ap-
proach to the development of angiogenesis inhibitors, have
paved the way for Sugen Inc. and Allergan Inc. to enter into
an exclusive collaboration to identify, develop and commercial-
ize novel pharmaceutical compounds utilizing Sugen’s proprie-
tary small-molecule signal transduction inhibition technology
(Hanks et al., 1988). In May 1997, Sugen announced the solu-
tion of the three-dimensional co-crystal structure of FGF
RTK with two of Sugen’s TK inhibitors. With this break-
through in crystallography, Sugen and its collaborators have
elucidated the structure of inhibitor compounds bound to the
active site of FGF receptor, enabling the research team to design
very speciﬁc and selective drug candidates, including Flk-1,
PDGF-R, as well as other types of protein kinases. Sugen’s
TK inhibitor compounds were initially identiﬁed by random
screening for selective inhibitors, thereby providing the basis
for adding computational chemistry and rational drug design
into Sugen’s technology platform (Hanks et al., 1988; Dengjel
et al., 2009).
Chronologically, in 1998, synthesis and biological evalua-
tions of a novel class of TK inhibitors were reported, where
3-substituted indolin-2-ones exhibited selectivity toward partic-
ular RTKs. Subsequently, SU-5416 was screened and proposed
as a potent and selective Flk-1/KDR kinase inhibitor that
blockaded receptor autophosphorylation, endothelial cell
mitogenesis and tumor cell growth (Fong et al., 1998, 1999).
Co-crystallization analysis revealed that SU-5416 binds at the
ATP domain of Flk-1/KDR, in essentially the same manner as
its counterpart SU-4984. Therefore, on the basis of crystallogra-
phy and the IC50 value on kinase activity of this and related com-
pounds, it can be inferred that the indolin-2-one core interferes
with the binding of the adenine core of ATP to RTK (Sun et al.,
1998; Toledo et al., 1999), thus preventing phosphate transfer to
the tyrosine residue. The fact that this particular substituted
indolin-2-one preferentially exists as the Z-isomer is important
for its speciﬁcity with regard to the Flk-1 tyrosine kinase. Syn-
thesis of 3-indolin-2-ones in 4 steps, 63 analogous prepared iso-
mer analysis in vitro tyrosine kinase activity (Sun et al., 1999,
2000; Sielecki et al., 2000;Krystal et al., 2001). Synthesis of indo-
lin-2-ones as potent and selective inhibitors of Flk-1/KDR for
the inhibition of tumor angiogenesis was subsequently docu-
mented. The 3-substituted indolin-2-ones 1–3 were initially
identiﬁed as potent inhibitors, although compound 2 was non-
selective with respect to other related receptor tyrosine kinases.
A number of structural modiﬁcations of these compounds led to
the conclusions that: (i) N1-methylation reduces activity; (ii)
placing electron-donating groups in the phenyl para position
provides high potency and selectivity (in contrast, installing elec-
tron-withdrawing substituents in this same position results in
inactive compounds); and (iii) methylation of the vinyl group
gave inactive analogs (Hanks et al., 1988).
Co-crystallization of an inhibitor with Flk-1 also provided
insight into the importance of the double bond stereochemistry.
In the bound structure of SU-4984, an analog of compound 2
where the isopropyl substituent was replaced by 4-methylpiper-
idine, the oxindole moiety occupied the ATP binding site.
Figure 5 A series of regulatory pathways involving the role of growth factors in promoting the process of angiogenesis, a hallmark
activity of developing tumor. (A) Angiogenesis inhibitors in the treatment of human cancer; these inhibitors fall into several different
categories, depending on their mechanism of action. Some inhibit endothelial cells directly, while others inhibit the angiogenesis signaling
cascade or block the ability of endothelial cells to break down the extracellular matrix. (B) Drugs that inhibit angiogenesis directly; one
class of angiogenesis inhibitors being tested in cancer patients are molecules that directly inhibit the growth of endothelial cells. Included in
this category is endostatin, the naturally occurring protein known to inhibit tumor growth in animals. Another drug, combretastatin A4,
causes growing endothelial cells to commit suicide (apoptosis). Other drugs, which interact with a molecule called integrin, also can
promote the destruction of proliferating endothelial cells. (C) Old drug with a new use; another interesting drug is thalidomide, a sedative
used in the 1950s that was subsequently taken off the market because it caused birth defects when taken by pregnant women. Although
this drug clearly would not be suitable for pregnant women, its ability to prevent endothelial cells from forming new blood vessels might
make it useful in treating non-pregnant cancer patients. (D) Drugs that block extracellular matrix breakdown; another group of
angiogenesis inhibitors are directed against one of the initial products made by growing endothelial cells, namely, the MMPs (matrix
metalloproteinases), enzymes that catalyze the breakdown of the extracellular matrix. Because breakdown of the matrix is required before
endothelial cells can migrate into surrounding tissues and proliferate into new blood vessels, drugs that target MMPs also can inhibit
angiogenesis. Several synthetic and naturally occurring molecules that inhibit the activity of MMPs are currently being tested to see if
interfering with this stage of angiogenesis will prolong the survival of cancer patients. (E) Drugs that block the angiogenesis signaling
cascade and the mechanism of action of Semazanib (SU-5416); an active group of angiogenesis inhibitors being tested in human clinical
trials are molecules that interfere with steps in the angiogenesis signaling cascade. Included in this category are anti-VEGF antibodies,
including Semazanib, that block the VEGF receptor from binding growth factor. Another agent, interferon-alpha, is a naturally occurring
protein that inhibits the production of bFGF and VEGF, preventing these growth factors from starting the signaling cascade. Also,
several synthetic drugs capable of interfering with endothelial cell receptors are being tested in cancer patients.
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mer, even though it was the E isomer in solution. Thus the E
form must be converted to the Z form before binding. Appar-
ently, this conversion was shown to be mediated by acid, base
or light. The pyrrole moiety of compound 3 was replaced with
other heterocycles (thiophene, furan, pyrazole), but the pyrrole
ring was the superior compound. In this series, all the E isomers
were inactive, and the vinyl proton was again determined to be
essential for activity (Hanks et al., 1988; Dengjel et al., 2009).
7. Semaxanib pharmacology and pharmacokinetics
Since its foundation in 1991, Sugen has focused on the devel-
opment of small-molecule drugs speciﬁcally targeting tyrosine
kinase, tyrosine phosphatase and serine-threonine kinase fam-
ilies of signal transduction molecules, and their signaling path-
ways (Antonian et al., 1999). Data on the pharmacology of
SU-5416, a novel synthetic compound, deals with its selectivity
and in vitro and in vivo efﬁcacy (Mendel et al., 2000b). SU-
5416, a potent and selective inhibitor of the Flk-1/KDR recep-
tor tyrosine kinase, was shown to inhibit vascular endothelial
growth factor-dependent mitogenesis of human endothelial
cells without inhibiting the growth of a variety of tumor cells
in vitro. Being part of the screening procedure to identify this
drug from a large pool of related compounds, SU-5416 is
highly effective as an inhibitor of Flk-1/KDR tyrosine kinase.
In cultured human endothelial cells (HUVECs), SU-5416
(0.1 lM) inhibited VEGF-stimulated thymidine uptake,
whereas FGF-1-stimulated thymidine uptake was inhibited
only at a concentration of 10 lM, further supporting selectiv-
ity of SU-5416 for the ﬂk-1 tyrosine kinase (Antonian et al.,
1999; Mendel et al., 2000b).
Although these in vitro data alone are insufﬁcient to demon-
strate the anti-angiogenic activity of SU-5416, further in vivo
data are available on various tumors in nude mice. Systemic
administration of SU-5416 at non-toxic doses in mice resulted
in the inhibition of subcutaneous tumor growth of cells derived
from various tissue origins. Speciﬁcally, SU-5416 in a dose of
25 mg/kg/day, reduced growth of a variety of tumors implanted
in nu/nu mice, with a follow-up varying from 13 to 38 days. The
anti-tumor effect of SU-5416 was accompanied by the appear-
ance of pale white tumors that were resected from drug-treated
animals, supporting the anti-angiogenic property of this agent.
No direct data were given on the vascularity of these tumors,
but a reduced vascularity was assumed on the basis of their pale
appearance. These ﬁndings support that pharmacological inhi-
bition of the enzymatic activity of the vascular endothelial
growth factor receptor represents a novel strategy for limiting
the growth of a wide variety of tumor types (Liekens et al.,
2001; Fong et al.,1998, 1999; Sun et al.,1998, 1999, 2000; Toledo
et al., 1999; Sielecki et al., 2000; Krystal et al., 2001; Antonian
et al., 1999; Mendel et al., 2000b).
The phosphorylation of the tyrosine residues in Flk-1/KDR
receptor leads to homo-dimerization of receptors (Bold et al.,
2000; Mendel et al., 2000c) and a sequence of events that is
generally believed to mediate the angiogenic effect of VEGF.
SU-5416 selectivity proﬁle is based on various phosphorylation
studies in appropriate cell lines and includes lack of inhibitory
effect on phosphorylation of the tyrosine residues of PDGF-R,
MAPK, EGFR, the insulin receptor (IR) and insulin receptor
substrate (IRS)-1. Only IRS-1 phosphorylation was inhibited
at a 100-fold higher concentration of SU-5416 than wasneeded to inhibit Flk-1 phosphorylation. Thus, as far as its
speciﬁc effect on receptor tyrosine phosphorylation is con-
cerned, SU-5416 can be considered selective for the Flk-1
receptor.
8. Semaxanib metabolism
SU-5416 has a short plasma half-life but prolonged in vivo ef-
fects in mouse tumor xenograft models and humans. In HU-
VECs, for example, SU-5416 did not inhibit VEGF-dependent
KDR phosphorylation by reducing the surface expression of
KDR, or the afﬁnity or amount of VEGF binding to KDR,
but probably by subcellular localization in cells. Furthermore,
it was shown that, in addition to inhibiting KDR/Flk-1 receptor
tyrosine kinase, SU-5416 also inhibits the Flt-1 receptor tyrosine
kinase and MAP kinase activity, and prevents VEGF-depen-
dent cell migration of vascular endothelial cells (Sun et al.,
1999, 2000; Sielecki et al., 2000; Krystal et al., 2001; Antonian
et al., 1999; Mendel et al., 2000b,c; Bold et al., 2000). A phase
II trial of SU-5416 in combinationwith standard-dose paclitaxel
(175 mg/m2, q3w) shows the regimen is well tolerated, with no
effect on paclitaxel pharmacokinetics. Su-5416 was also studied
at doses of 85 or 145 mg/m2 twice weekly in combination with
ﬂuorouracil and leucovorin (given either weekly or daily for
5 days every 4 weeks) in patients with untreated metastatic co-
lon cancer. The response rate was 36% with a time to progres-
sion of 9 months, a time to failure of 8.5 months and a median
survival time of 22.6 months (Antonian et al., 1999; Mendel
et al., 2000b). These results were compared with historical data
from a phase III study of ﬂuorouracil and leucovorin with or
without irinotecan (CPT-11; Yakult Honsha KK/Daiichi
Seiyaku Co. Ltd./Pharmacia Corp.). The time to progression
and survival time appeared to be better than in the arm compris-
ing ﬂuorouracil and leucovorin alone and similar to the arm that
included irinotecan (Sun et al., 1999, 2000; Sielecki et al., 2000;
Krystal et al., 2001; Antonian et al., 1999;Mendel et al., 2000b).
Another extensive study was designed to investigate the
in vitro metabolism of SU-5416 by mouse, rat, dog, monkey,
and human liver microsomes and to identify the major metab-
olites of SU-5416. A high-pressure liquid chromatography
(HPLC) procedure analysis was developed and validated to re-
solve and quantify SU-5416 and its metabolites. To evaluate
the in vitro metabolism of SU-5416, pooled liver microsomes
from mice, rats, dogs, monkeys, and humans were incubated
with SU-5416 (25 lM) in the presence of an NADPH-generat-
ing system. In the presence of NADPH, mouse, rat, dog, mon-
key, and human liver microsomes converted SU-5416 to at
least 12, 9, 9, 7, and 6 polar metabolites, respectively (Sun
et al., 1998, 1999, 2000; Toledo et al., 1999; Sielecki et al.,
2000).
Microsomal metabolism of SU-5416 showed marked species
differences in the levels of different metabolites formed. The
overall rate of SU-5416 metabolism by liver microsomes from
the species examined followed the rank order: mon-
keyP mouse  rat > dog > human. Two major metabolites
of SU-5416 were identiﬁed, a hydroxymethyl derivative of SU-
5416 (M12) and a carboxylic acid derivative of SU-5416 (M6),
by spectroscopic methods and comparison with authentic com-
pounds. Both of these oxidativemetabolites were furthermetab-
olized in vivo through glucuronidation. The metabolic fate of
SU-5416 in microsomes from various species as well as data
from in vivo biotransformation in the rat was assessed and
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et al., 2001; Antonian et al., 1999; Mendel et al., 2000b; Bold
et al., 2000).
9. Semaxanib toxicity and cytotoxicity – contraindications
SU-5416 was investigated in phase I dose escalating trials in pa-
tients with advancedmalignancies. The drug exhibited onlymild
toxicity, and the elimination t1/2 was approximately 50 min. A
dose level of 145 mg/m2 was subsequently recommended for
phase II trials, based on AUC. Of note, some comparative
differences were reported in the context toxicity proﬁle in rats
following intravenous (i.v.) administration of SU-5416 and
SU-6668, another tyrosine kinase inhibitor developed by Sugen
(Sun et al., 1999, 2000; Sielecki et al., 2000; Krystal et al., 2001;
Antonian et al., 1999; Mendel et al., 2000b). Furthermore, in a
phase I/II study of SU-5416 in combination with 5-FU in
patients with metastatic colorectal cancer administered with
SU-5416 (85 and 145 mg/m2) twice weekly, combined with a
standard dose of 5-FU, it was described that 5-FU dose-limiting
toxicities (DLTs) predominated; no SU-5416-related DLTs
have been observed. The metabolic pharmacokinetics of the
combination, in addition, was not signiﬁcantly different from
SU-5416 administered alone (Sun et al., 1999, 2000; Sielecki
et al., 2000; Krystal et al., 2001; Antonian et al., 1999; Mendel
et al., 2000b,c; Bold et al., 2000).
During the 36th annual meeting of the American Society of
Clinical Oncology in New Orleans, LA, USA, a detailed dose
escalating study of SU-5416 in AIDS-related Kaposi’s sarcoma
was reported. SU-5416, a selective antagonist of Flk-1 located in
stromal vessels around lesions, caused decreased VEGF phos-
phorylation, dimerization, and signaling. Men with Kapos’s
sarcoma received doses of 65–145 mg/m2 i.v. biw for six cycles
(of 29 days). There was no effect on CD4 count or viral load,
but 10% had grade 3 migraine headaches that responded to
sumatriptan (GlaxoWellcome plc.) and 11 had phlebitis, requir-
ing the use of central catheters. Reduced clearance occurred over
time, most likely due to concomitantly administered protease
inhibitors. Five responses and clinical improvement (which con-
sisted of decreased edema and improved performance status)
were observed in nine patients (Sun et al., 1999, 2000; Sielecki
et al., 2000; Krystal et al., 2001; Antonian et al., 1999; Mendel
et al., 2000b,c; Bold et al., 2000).
Furthermore, it was reported that in a phase I study of SU-
5416 in patients with a variety of tumor types, tumor vascular
permeability wasmeasured with dynamic contrastMRI to dem-
onstrate that no dose limiting toxicity was seen at doses 48–
190 mg/m2 bi-weekly · 4 weeks. Intrapatient dose escalation
was permitted because the diluent for this agent is cremaphor,
and so steroids and histamine blockers were administered
(Vacca et al., 2000; Philip, 2000; Liekens et al., 2001; Fong
et al., 1998, 1999; Sun et al., 1998, 1999; Toledo et al., 1999).
There were no clinical responses, but six patients had tumor
stabilization and in four of these, decreased tumor vascular per-
meability was seen. The investigators controlled the effect of the
steroids on permeability, by performing scans before treatment
with steroids also given. Another study reported a detailed phase
I study of SU-5416 given as a 5-day load followed by 5-weekly
maintenance infusions with the ﬁnal doses achieved being
65 mg/m2 load and 190 mg/m2/week. Grade 3 headaches were
themost signiﬁcant toxicity. One patient with squamous cell car-
cinoma of the lung had a PR and three patients had SD. In addi-tion, data were presented for a phase I/II study of SU-5416 given
at escalating doses of 85–145 mg/m2 i.v. biw alongwith 5-ﬂuoro-
uracil and leucovorin to patients with metastatic colon cancer.
No dose limiting toxicity attributable to the SU-5416 was ob-
served. The chemotherapy did not alter SU-5416 pharmacoki-
netics. Patient responses included a complete response (CR),
ﬁve PRs and nine patients with SD. In short, toxicities reported
to date in patients treated with SU-5416 included headaches and
gastrointestinal events, such as nausea, vomiting and diarrhea.
More data for SU-5416 were presented, including a phase I/
II study in combination with paclitaxel and carboplatin, and a
phase I study of an oral formulation. In the combined chemo-
therapy/Semaxanib study, full doses of carboplatin and paclit-
axel and doses of SU-5416 (less than or equal to 145 mg/m2 i.v.
twice weekly) were well tolerated, with no increases in throm-
bocytopenia, neutropenia or peripheral neuropathy, compared
with toxicities reported for carboplatin and paclitaxel alone.
Although paclitaxel and carboplatin PKs were not affected
by SU-5416, the clearance of Semaxanib was reduced when gi-
ven with paclitaxel, resulting in an increased AUC and sys-
temic exposure. Among the 25 patients, there were four CRs
and one PR (Liekens et al., 2001; Fong et al., 1998, 1999;
Sun et al., 1998, 1999, 2000; Toledo et al., 1999; Sielecki
et al., 2000; Krystal et al., 2001; Antonian et al., 1999; Mendel
et al., 2000). In the study of the oral formulation, oral bioavail-
ability was 45% when dosed in orange juice. Clearance was
generally higher for oral vs. i.v. administration. Toxicities were
mild but the taste of the drug was considered to be poor
(Liekens et al., 2001; Fong et al., 1998, 1999; Sun et al., 1998,
1999, 2000; Toledo et al., 1999; Sielecki et al., 2000; Krystal
et al., 2001; Antonian et al., 1999; Mendel et al., 2000b,c; Bold
et al., 2000; Smolich et al., 2001). Further work to improve the
oral formulation is under way in order to use the drug on a
more chronic basis for less advanced malignancies.
10. Semaxanib clinical development
10.1. Pre-clinical studies
An independent report on in vitro and in vivo efﬁcacy of SU-5416
was published in 1997. Increased vascular permeability and
excessive neo-vascularization are the hallmarks of endothelial
dysfunction, which can lead to diabetic macular edema and pro-
liferative diabetic retinopathy. VEGF was shown to be an
important mediator of ocular neo-vascularization and a known
vaso-permeability factor in non-ocular tissues (Mendel et al.,
2000b,c; Bold et al., 2000; Smolich et al., 2001). In these studies,
it was demonstrated that intra-vitreal injection ofVEGF rapidly
activated protein kinase C (PKC) in the retina at concentrations
observed clinically, inducing membrane translocation of PKC
isoforms a, bII, and d and >threefold increases in retinal
vaso-permeability in vivo. The effect of VEGF on retinal
vascular permeability appeared to be mediated predomi-
nantly by the b-isoform of PKC with >95% inhibition of
VEGF-induced permeability by intra-vitreal or oral administra-
tion of a PKC b-isoform-selective inhibitor that did not inhibit
histamine-mediated effects.
In the HUVEC assay, a 3,5-dimethyl pyrrole-analog (SU-
5416) was the superior compound, with an IC50 of 40 nM.
The compound was also highly selective for Flk-1, being essen-
tially inactive at other related tyrosine kinase receptors, such as
PDGF, EGF and IGF-1. SU-5416 was chosen for further
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binds at the ATP domain of Flk-1 in essentially the same man-
ner as SU-4984. SU-5416 displayed dose-dependent inhibition
of subcutaneous growth of A375 human melanoma in mice,
and in preclinical studies, no toxic effects were noted at efﬁca-
cious doses (Krystal et al., 2001; Antonian et al., 1999; Mendel
et al., 2000b,c; Bold et al., 2000). This compound dramatically
inhibited tumor size and tumor neo-vascularization, suggesting
that tumor growth is not affected directly. SU-5416 displayed a
broad anti-tumor spectrum: i.p. administration inhibited eight
of 10 different cell lines grown subcutaneously in mice.
Although the plasma half-life was short (30 min), the half-life
for activity against Flk-1 was about 20 h, perhaps due to the
lipophilicity of the compound.
SU-5416, among other candidate inhibitors, was screened
as potent anti-angiogenic small-molecule inhibitor of receptor
tyrosine kinases, including those of the VEGF and PDGF
receptor families. The stem cell factor (SCF) receptor, c-kit,
is structurally related to these receptors and, although not ex-
pressed on mature peripheral blood cells, is expressed in leuke-
mic blasts derived from 60% to 80% of acute myeloid
leukemia (AML) patients. The c-kit kinase inhibitory activity
of SU-5416 was evaluated in MO7E cells, a human myeloid
leukemia cell line. Tyrosine autophosphorylation of the recep-
tor, induced by SCF, was inhibited in these cells by SU-5416 in
a dose-dependent manner (inhibitory concentration of 50%
[IC50] = 0.1–1 lM) (Smolich et al., 2001).
Inhibition of extracellular signal-regulated kinase 1/2
(ERK1/2) phosphorylation, a signaling event downstream of
c-kit activation, was also inhibited in a dose-dependent manner
(Vajkoczy et al., 2000; Ellis et al., 2000; Puduvalli and Sawaya,
2000; Liekens et al., 2001; Brostjan et al., 2000; Mitsuyasu,
2000; Ryan and Wilding, 2000; Deplanque and Harris, 2000;
Vacca et al., 2000). SU-5416 also inhibited SCF-induced pro-
liferation of MO7E cells (IC50 = 0.1 lM). Furthermore, SU-
5416 induced apoptosis in a dose- and time-dependent manner
as measured by the increase in activated caspase-3 and the en-
hanced cleavage of its substrate poly(ADP-ribose) polymerase
(Smolich et al., 2001). These ﬁndings with MO7E cells were ex-
tended to leukemic blasts from c-kit (+) patients. In patient
blasts, SU-5416 inhibited SCF-induced phosphorylation of c-
kit and ERK1/2 and induced apoptosis. These studies indi-
cated that SU-5416 inhibited biologic functions of c-kit in
addition to exhibiting anti-angiogenic properties and suggested
that the combination of these activities may provide a novel
therapeutic approach for the treatment of AML (Smolich
et al., 2001).
10.2. Clinical investigations
In January 1997, Sugen announced that the company’s Flk-1
TK angiogenesis inhibitor program will move into human clin-
ical studies in mid-1997. The objective of the angiogenesis clin-
ical program was to establish the safety and efﬁcacy of the
company’s lead drug candidate as an anti-metastasis and angio-
genesis inhibitory treatment for solid tumor cancers. The com-
pany has identiﬁed several small-molecule inhibitors of the
Flk-1 receptor that meet its pre-clinical proﬁle for an IND can-
didate in this program, and has proceeded into pharmacology
and pharmaceutical development. It was subsequently planned
to assess comprehensive human safety studies by late 1997, in or-
der to permit the commencement of the ﬁrst efﬁcacy studies withthe ﬁnal drug candidate around the end of the year (Smolich
et al., 2001).
Sugen’s animal studies have shown that Flk-1 TK inhibi-
tors, including SU-5416, blocked the growth of most solid
tumors by angiogenesis inhibition, and as a cause of death in
many tumor types (Fig. 5) (Le et al., 1993; Plate, 1996; Ono
et al., 1997; Neufeld et al., 1999; Ware and Simon, 1997;
Folkman, 1995; Aiello et al., 1997). This was an important
discovery because it demonstrated the potential utility of these
compounds as part of a front-line therapy regimen, in addition
to their applications in chronic therapy. In July 1997, Sugen
announced that the company has ﬁled an IND application with
the FDA for the clinical testing of a synthetic small-molecule
signal transduction inhibitor of Flk-1/KDR that has therapeu-
tic potential as an anti-angiogenesis and anti-metastasis agent
in solid tumor cancer patients.
In September 1997, Sugen announced that it has initiated the
ﬁrst phase I clinical trial of its angiogenesis inhibitor, SU-5416,
for the treatment of solid tumors and tumormetastases. The tar-
get for this angiogenesis inhibitor is Flk-1/KDR, a molecular
driver of blood vessel formation, which has been validated by
Sugen scientists in collaboration with the Max Planck Institute.
The phase I clinical study was being conducted under the guid-
ance of Lee Rosen,MD, Director of the Jonson Comprehensive
Cancer Center and the Cancer Therapy Development Program
at the UCLA School of Medicine in Los Angeles, California,
where the ﬁrst patient went on study. The objective of this phase
I trial was to assess the safety and dosage range of SU-5416
(Hanks et al., 1988). This study recruited patients with advanced
malignancies who have failed previous drug therapy. Dosing
was administered intravenously on a twice-weekly schedule
and continued until unacceptable toxicity or progression of dis-
ease was seen. The study recruited approximately 30 patients
and tookup to sixmonths to complete. In addition to the i.v. for-
mulation used in phase I study, scientists have succeeded in
developing an oral formulation for SU-5416 that has demon-
strated bioavailability in animals (Sun et al., 1999, 2000; Sielecki
et al., 2000; Krystal et al., 2001; Antonian et al., 1999; Mendel
et al., 2000b,c; Bold et al., 2000; Smolich et al., 2001).
This advance appeared to have cleared the way to introduce
an oral dosage form, which was expected to enter into clinical
trials in 1998 (Neufeld et al., 1999; Ware and Simon, 1997;
Folkman, 1995; Aiello et al., 1997; Aiello et al., 1994; Brown
et al., 1995; Dumas, 2001; McMahon, 2000). In May 1998, Su-
gen announced the initiation of a phase I/II study to investigate
the safety and efﬁcacy of SU-5416 in patients with Kaposi’s sar-
comawho have failed currently available therapy. The study, ex-
pected to enroll 30 patients, was conducted at ﬁve US medical
centers specializing in AIDS-related malignancies. The study
endpoints included measurement of objective response and
time-to-disease progression in addition to safety and pharmaco-
kinetic parameters.
Interim phase I data of SU-5416 was presented at ASCO in
1998. To that date the study had enrolled at least 30 patientswith
advanced solid tumormalignancies, and indicated that SU-5416
waswell tolerated at a dose range of 4.4–65 mg/m2. Patientswith
advanced malignancies, including those with colorectal and
lung cancer, have been treated in the phase I dose-escalation
study, which began in September 1997. SU-5416 was adminis-
tered twice weekly in an i.v. formulation, with escalating doses
up to a level of 145 mg/m2 (from an original starting dose of
4.4 mg/m2). SU-5416 was shown to be well tolerated with only
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ache, pain at injection site). In patients treated for longer than
six months, there had been no evidence of cumulative or chronic
toxicities, indicating SU-5416’s potential use for chronic admin-
istration (Seetharam et al., 1995; Sun and McMahon, 2000;
Quinn et al., 1993; Gerber et al., 1998; Soker et al., 1998; Strawn
et al., 1996; Shawver, 1999; Shalaby et al., 1995; Millauer et al.,
1994).
Pharmacokinetics data showed that the levels of SU-5416 de-
tected in patient serum exceeded those predicted to be necessary
to achieve an anti-angiogenesis effect based on preclinical ani-
mal studies. While phase I trials were not designed to measure
efﬁcacy, there have been observations of lesion shrinkage in
Kaposi’s sarcoma, colorectal and basal cell cancer patients.
Eight of these advanced disease patients (12%) remained on
study for over six months, and another 14 patients (20%) re-
mained on study for more than three months without any dis-
ease progression. Five out of 11 non-small cell lung cancer
patients remained on study for over 150 days, including one pa-
tient who has remained on study for over 390 days. The phase I
clinical trial, designed to assess the safety of SU-5416 in the esca-
lating dose study, had demonstrated that, SU-5416 could be
safely administered at the doses given. These investigations pre-
pared the ground for the launch ofmultiple phase II studies later
in 1998 (Mendel et al., 2000b,c; Bold et al., 2000; Smolich et al.,
2001).
The clinical strategy for SU-5416 continued to focus pri-
marily on the potential utility of this drug as a tumor growth
inhibitor and anti-metastatic agent in solid tumor patient pop-
ulations. In addition to Kaposi’s sarcoma study, Sugen
planned to initiate multiple phase II trials in the course of
1998 to investigate the potential efﬁcacy of SU-5416 in differ-
ent solid tumor cancer indications. The phase I/II trial was
conducted at the Cancer Research Campaign (CRC) Center
for Cancer Therapeutics at the Institute for Cancer Research
(ICR) and the Royal Marsden Hospital (RMH) in London.
The study included 24 patients and assessed leakiness of tumor
blood vessels as a biological marker for the angiogenic process
using imaging methods, in addition to monitoring safety and
pharmacokinetic parameters. By measuring the change in
leakiness of the tumor blood vessels, a very early indication
of how effective SU-5416 was at blocking the unwanted signals
in human cancers was determined (Toledo et al., 1999; Sun
et al., 1999, 2000; Sielecki et al., 2000).
In May 1999, it was announced that Sugen intended to col-
laborate with the National Cancer Institute (NCI) on multiple
phase II and I/II studies of SU-5416, to be conducted at approx-
imately 20 leading cancer centers around the country. Under the
Clinical Trials Agreement, the NCI had selected more than 20
studies out of 51 proposals from investigators at cancer centers
and clinical research hospitals throughout the US to test SU-
5416 as either a single agent or in combination with the other
drugs in a variety of cancer indications. Between 500 and 700 pa-
tients were expected to be enrolled in these NCI-sponsored tri-
als. SU-5416 was used as single agent therapy in several phase
II studies, including renal, head and neck, sarcoma, and prostate
cancers. SU-5416 was also tested in several phase I/II studies in
combination with standard and investigational chemotherapy
in patients with advancedmalignancies, including colorectal, re-
nal, ovarian, and breast cancers, and certain leukemias (Traxler
and Furet, 1999; Arasteh and Hannah, 2000; Vajkoczy et al.,
2000; Ellis et al., 2000; Puduvalli and Sawaya, 2000; Liekenset al., 2001; Brostjan et al., 2000; Mitsuyasu, 2000; Ryan and
Wilding, 2000; Deplanque and Harris, 2000; Vacca et al.,
2000; Philip, 2000; Liekens et al., 2001; Fong et al., 1998,
1999; Sun et al., 1998, 1999; Toledo et al., 1999).
These trials helped set the stage for potentially broad use of
SU-5416 in a variety of therapeutic settings. Furthermore, a
phase I/II study of SU-5416 in combination with 5-Flurouracil
(FU)/Leucovorin (LV) in patients with metastatic colorectal
cancer was presented in May 2000. The phase I/II study evalu-
ated 28 patients to determine the safety and tolerability of
SU-5416when used in combinationwith 5-FU/LVPatients with
untreated advanced colorectal cancer were treated with increas-
ing doses of SU-5416 (85 and 145 mg/m2) administered intrave-
nously twice each week, in combination with standard doses of
5-FU/LV therapy. In a preliminary analysis of this data, it was
shown that patients receiving SU-5416 were found to be free of
tumor growth and spread for a median time in excess of
9.2 months. Of the 28 patients who participated in the study,
data to date show 41% had an objective response (either com-
plete or partial responsewith 50%or greater shrinkage of tumor
size). Safety data showed no dose-limiting toxicity attributable
to SU-5416, with three patients remaining on therapy for more
than one year. Toxicities were predominantly those known to
occur with 5-FU/LV, including severe nausea, vomiting, diar-
rhea, mucositis and neutropenia (Sun et al., 1999, 2000; Sielecki
et al., 2000; Krystal et al., 2001; Antonian et al., 1999; Mendel
et al., 2000b,c; Bold et al., 2000; Smolich et al., 2001).
In January 1999, Sugen announced today that it planned to
accelerate the development of its lead angiogenesis inhibitor,
SU-5416, moving directly from phase I and phase I/II studies
into phase III colorectal and lung studies, and a phase II/III
study in AIDS-related Kaposi’s sarcoma. Pending discussions
with the FDA, both the phase III colorectal and lung studies
were intended to compare the efﬁcacy of standard chemother-
apy regimens to those same regimens in combination with
SU-5416. The equivalent of phase II data was gathered and
analyzed at scheduled interim reviews. In March 1999,
SU-5416 entered phase II/III clinical trials for AIDS related
Kaposi’s sarcoma. In June 1999, Sugen announced that
FDA had agreed with the company’s proposed clinical trial
design for phase III trials of SU-5416, its lead angiogenesis
inhibitor, in colorectal and non-small cell lung cancer (Liekens
et al., 2001; Fong et al., 1998, 1999; Sun et al., 1998, 1999,
2000; Toledo et al., 1999; Sielecki et al., 2000; Krystal et al.,
2001; Antonian et al., 1999; Mendel et al., 2000b).
The trials, which began in the US and Europe, compared
SU-5416 against standard chemotherapy regimens in patients
who have not yet received any chemotherapy. Both trials pro-
vided for scheduled interim analyses. The primary endpoint
was survival, with secondary endpoints of time-to-disease pro-
gression and objective response rate (Stover et al., 1999;
Traxler and Furet, 1999; Arasteh and Hannah, 2000; Vajkoczy
et al., 2000; Ellis et al., 2000; Puduvalli and Sawaya, 2000;
Liekens et al., 2001; Brostjan et al., 2000; Mitsuyasu, 2000;
Ryan and Wilding, 2000; Deplanque and Harris, 2000; Vacca
et al., 2000). The studies analyzed tumor samples, using
Sugen’s proprietary gene expression array technology.
11. Semaxanib side effects and contraindications
Side effects and contraindications associated with SU-5416
reported to date (that the time of the actual performance of
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testinal complications, such as nausea, vomiting and diarrhea,
mucositis and neutropenia. Apart from that, no detailed data
are currently available on the side effects and contraindications
associated with SU-5416 administration. What the author has
concluded from the aforementioned is that the stage at which
Semaxanib was withdrawn from further experimentation and
clinical trials was crucial at initiating the emerging of a new
generation of RTK/VEGF regulators that are showing solid
grounds in the therapeutic treatment of cancer via the regula-
tion of angiogenesis (see Fig. 5).12. Current therapy and opinion – the case of bevacizumab
(Avastin) and the anti-angiogenesis connection
Since ﬁrst proposed few decades earlier, angiogenesis has been
coined as an important and crucial factor in the etiology ofmany
human diseases. In cancer, an assessment of tumor-associated
angiogenesis has been particularly viewed as a potential indica-
tor of tumor aggressiveness and patient prognosis. Of note,
anti-angiogenesis therapy have been already investigated in
pre-clinical models in combination with more traditional
cytotoxic therapies, and many clinical studies are currently
addressing the efﬁcacy and safety of a combination of angiogen-
esis inhibitors and the conventional anti-cancer approaches,
such as radiation and chemotherapy. These aforementioned
approaches, which have incorporated a strategy to develop
and commercialize selective inhibitors of RTKs, might certainly
provide a novel method for the development of new agents for
the treatment of human cancers and other associated diseases
(see Figs. 2 and 5).
In recent years, the network of signal transduction path-
ways has been largely deciphered, thereby making more clearly
the factor that any aberration in signaling elements is the root
of many diseases. For instance, many of the known oncogenes
and proto-oncogenes code for RTKs. This realization has
identiﬁed these proteins as potential targets for disease ther-
apy. Thus the concept of ‘‘signal transduction therapy’’ takes
on a broader insight and can apply to proliferative diseases,
such as cancers, psoriasis and retinosis, as well as inﬂamma-
tory conditions, such as sepsis and multiple sclerosis. Appar-
ently, agents that directly or indirectly modulate any of the
converging transduction pathways targeting speciﬁc compo-
nents would be introduced as a means to combating the path-
ologic condition (Haddad, 2001, 2004).
One such novel approach is the development of SU-
5416, as a selective inhibitor of Flk-1/KDR kinase with
an effective anti-angiogenesis and anti-tumorigenesis ther-
apy. The mechanism of action and the selectivity proﬁle
makes SU-5416 an interesting and promising drug among
a growing number of anti-angiogenic agents that aim to re-
duce or halt tumor growth. Prospects for continued devel-
opment and evaluation in pre-clinical as well as clinical
investigations are certainly outstanding and have proven
to be efﬁcacious. Despite the fact that competition in this
ﬁeld is ﬁerce, the selectivity proﬁle of the SU-5416 gives
it a unique place in anti-angiogenic strategies. It is un-
known, however, whether in tumor treatment such selectiv-
ity is warranted or beneﬁcial, but even if multi-target
approaches are being devised, it is likely that a selective
anti-VEGF arm is part of such a strategy.In the light of the aforementioned, I would want to point
the reader’s attention to current developments in anti-VEGF
therapy, particularly shedding light on the FDA-approved
monoclonal chimera dubbed bevacizumab (Avastin). Given
this understanding, I can now ask from where the next gener-
ation of targeted therapies will arise. Clearly, VEGFR and
EGFR signaling are validated target pathways for new treat-
ments for colorectal cancer, the initial point of focus of
Semaxanib. The following excerpts are highlighted from the
acclaimed reference of Colorectal Cancer: Evidence-Based
Chemotherapy Strategies, edited by Leonard B. Saltz, 2007
(Humana Press, an imprint of Springer-Verlag) (Saltz, 2007).
‘‘Bevacizumab (Avastin)’’, a humanized antibody directed
against VEGF, has demonstrated signiﬁcant survival beneﬁts
when added to traditional chemotherapy in both the ﬁrst-
and second-line setting in metastatic colorectal cancer. The
toxicities of bevacizumab appear modest relative to those of
most cytotoxic chemotherapy. In addition to bevacizumab,
several other promising agents are in late stages of clinical
development. Important questions, particularly regarding
duration of use, remain to be addressed in well-designed clin-
ical trials.
As indicated, bevacizumab is a humanized antibody directed
against the VEGFR-1 and -2 ligands. Preclinical studies demon-
strated that bevacizumab binds to and neutralizes all human
VEGF-A isoforms. In addition to its direct anti-angiogenic ef-
fects, bevacizumabmay also improve the delivery of chemother-
apy by reducing interstitial pressure in tumors. Phase I clinical
trials initiated in 1997 showed that the antibody was relatively
nontoxic as a single agent, and that adding it to standard chemo-
therapy did not signiﬁcantly increase chemotherapy-associated
toxicities. More encouraging efﬁcacy results were seen when
bevacizumab was combined with standard chemotherapeutic
agents in CRC.
In an early randomized phase II trial, 104 previously un-
treated patients with metastatic CRC were randomly assigned
to 5-ﬂuorouracil (5-FU)/leucovorin (LV) (5-FU 500 mg/m2
and LV 500 mg/m2 once weekly for the ﬁrst 6 weeks of an 8-
wk cycle) alone or with bevacizumab at one of two different
doses (either 5 or 10 mg/kg every 2 weeks). Comparing the
5 mg/kg dose with 5-FU alone demonstrated differences in re-
sponse rate (40% vs. 17%), time to tumor progression (9 vs.
5.2 months), and median OS (21.5 vs. 13.8 months), and this
dose was recommended for further use/testing. Higher-dose
bevacizumab therapy plus chemotherapy did not offer further
potential gains and indeed might have been inferior to lower
dose drug. Thrombosis was the most signiﬁcant adverse event
(10.4% grade 3/4) and was fatal in one person, and grade 3/4
hypertension was seen in 16.4% of patients. In addition,
25.3% of patients receiving bevacizumab developed protein-
uria or experienced worsening proteinuria. It is not clear
why the 5 mg/kg dose of bevacizumab seemed to be more
effective than the 10 mg/kg dose, though this was not a phase
III trial designed to speciﬁcally compare the three arms in
terms of efﬁcacy, and it was pointed out that any imbalance
in randomization in this relatively small study could have led
to a higher number of poor-prognosis patients in the high-dose
arm. The Eastern Cooperative Oncology Group (ECOG) has
evaluated the combination of irinotecan, 5-FU/LV (IFL),
and bevacizumab in patients with previously untreated
advanced colorectal cancer in a phase II study (E2200). The
ﬁrst 20 patients received irinotecan (125 mg/m2), 5-FU
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higher-dose bevacizumab (10 mg/kg) every other week. Fol-
lowing a toxicity review of other trials using IFL, subsequent
patients were enrolled at reduced starting doses of irinotecan
(100 mg/m2) and 5-FU (400 mg/m2). Preliminary results are
available for the ﬁrst 87 patients. Although 36% of patients
experienced grade 3/4 neutropenia, febrile neutropenia was
uncommon (5%). There was one grade 4 epistaxis (requiring
tamponade but no transfusion) and two grade 3 melena. There
were six grade 3 thrombotic events and three grade 4 events
(pulmonary embolism). Proteinuria and hypertension were
infrequent. Overall response rate was 49%, and median pro-
gression-free survival (PFS) was 10 months. Median overall
survival (OS) has not been reported, although the 1-yr OS rate
was 85%.
In a subsequent pivotal phase III trial, 813 patients with
previously untreated metastatic colorectal cancer were ran-
domized to receive IFL plus either bevacizumab (5 mg/kg
every 2 weeks) or placebo. A third treatment arm consisting
of 5-FU/LV plus bevacizumab enrolled 110 patients before a
planned interim safety analysis established an acceptable safety
proﬁle for the IFL plus bevacizumab treatment group; at that
time, 100 patients had also been randomized to the IFL plus
placebo treatment arm. The addition of bevacizumab im-
proved median OS (20.3 vs. 15.6 months), PFS (10.6 vs.
6.2 months), and response rate (44.8% vs. 34.8%) compared
with bolus IFL alone. Grade 3 hypertension was more com-
mon during treatment with IFL plus bevacizumab than with
IFL plus placebo (11% vs. 2.3%), but was easily managed with
standard antihypertensives. Unlike in the previously discussed
phase II trial, no appreciable increases in thrombosis, bleeding,
or proteinuria occurred with the addition of bevacizumab.
However, bowel perforation occurred in 1.5% of patients
receiving IFL plus bevacizumab, and one patient died as a di-
rect result of this event. Based on the convincing proof of efﬁ-
cacy when added to IFL and 5-FU/LV as ﬁrst-line treatment,
bevacizumab was approved by the FDA in 2004 for use in the
ﬁrst-line setting in combination with intravenous 5-FU-based
therapy.
An interesting randomized, placebo-controlled phase II
study was conducted concurrently with the pivotal trial in pa-
tients deemed nonoptimal candidates for ﬁrst-line irinotecan-
containing regimens. Patients were required to have at least
one of the following adverse characteristics: age 65 years or
older, ECOG performing status (PS) of 1 or 2, serum albumin
no more than 3.5 g/dL, or prior radiotherapy to abdomen or
pelvis. A total of 209 patients were randomized to weekly 5-
FU/LV plus either lower dose bevacizumab or placebo.
Despite this higher risk study population, the regimen of 5-
FU/LV plus bevacizumab appeared to be well tolerated. Pa-
tients receiving bevacizumab had a higher incidence of grade
3 hypertension (16% vs. 3%) and arterial thrombotic events
(10% vs. 5%), but no differences were seen in venous throm-
bosis, grade 3/4 bleeding, or clinically signiﬁcant proteinuria.
The addition of bevacizumab to 5-FU/LV was associated with
numerically superior median PFS (9.2 vs. 5.5 months) and re-
sponse rates (26% vs. 15.2%) compared to 5-FU/LV alone.
OS, the primary end point of the study, was longer in the
group receiving bevacizumab (16.6 vs. 12.9 months), but this
difference did not reach statistical signiﬁcance. Despite the fact
that these patients were deemed unﬁt for ﬁrst-line irinotecan,the authors suggested that one possible explanation for the
lack of a survival beneﬁt is that more than 40% of patients re-
ceived potentially effective post-progression therapy with iri-
notecan and/or oxaliplatin, conceivably diluting any survival
advantage from ﬁrst line therapy containing bevacizumab.
A combined analysis of raw primary data from three
clinical trials further evaluated the addition of bevacizumab
to 5-FU/LV. These three studies consisted of the two phase
II studies discussed previously and the third treatment group
in the pivotal randomized phase III trial (5-FU/LV plus
bevacizumab). In the combined analysis of the three studies,
249 patients had received 5-FU/LV plus bevacizumab, and
241 patients had received either 5-FU/LV (n= 141 patients)
or bolus IFL (n= 100 patients) without the addition of the
anti-angiogenic agent. Stratiﬁed analysis showed that the
patients receiving bevacizumab realized a signiﬁcant increase
in median survival (17.9 vs. 14.6 months), PFS (8.8 vs.
5.6 months), and response rate (34.1% vs. 24.5%) relative to
patients receiving cytotoxic chemotherapy alone.
Oxaliplatin-containing regimens are also highly active
against colorectal cancer, and investigators have combined
FOLFOX with bevacizumab in the front-line setting. The
TREE1 study randomized 147 previously untreated patients
to one of three oxaliplatin/ﬂuoropyrimidine regimens
(mFOLFOX6, bolus 5-FU/oxaliplatin [bFOL], or capecita-
bine + oxaliplatin [CapOx]). Objective tumor responses were
seen in 24–39% of patients in the three arms. The TREE2
study had identical eligibility criteria and then randomized
210 patients to one of the same three regimens (although the
capecitabine dose was reduced from 1000 mg/m2 twice daily
[TREE1] to 850 mg/m2 twice daily [TREE2] after excess toxic-
ity was seen at the higher dose level), plus bevacizumab at a
dose of either 5 mg/kg every 2 weeks (FOLFOX, bFOL) or
7.5 mg/kg every 3 weeks (CapOx). The addition of bev-
acizumab resulted in higher response rates in all three arms
of the TREE2 study compared to the TREE1 study, as overall
response rates were seen in 34–49% of patients. There ap-
peared to be no signiﬁcant additive toxicity with bevacizumab.
It should be noted that patients were randomized within
TREE1 and TREE2, but that patients were not randomized
between these two studies. Therefore, conclusions regarding
the beneﬁt of bevacizumab should be made cautiously. Numer-
ous additional studies are either ongoing or planned to further
examine the role of anti-angiogenesis strategies in the upfront
treatment of advanced CRC. An industry-sponsored trial (No.
16966) randomized approximately 1500 previously untreated
patients to either CapOx or FOLFOX4, with or without bev-
acizumab (dosed at 5 mg/kg every 2 weeks with FOLFOX4 or
at 7.5 mg/kg every 3 weeks with CapOx), with its primary end
point being PFS. This predominantly European study easily
completed accrual prior to the commercial availability of bev-
acizumab in Europe, despite the fact that a similar National
Cancer Institute (NCI) Intergroup study opened in the United
States and closed prematurely when it became apparent that
American patients, who had access to bevacizumab commer-
cially, would not accept potential treatment on a study with
nonbiological containing arms. A large, phase III Intergroup
trial coordinated by the Southwest Oncology Group (SWOG)
and the Cancer and Leukemia Group B (CALGB) activated
in September 2005. This trial permits investigators to
select upfront chemotherapy for individual patients (either
Table 1 SU-5416 at a glimpse.
Originator: Sugen Inc., USA
Status: Phases I, II and III clinical trials; discontinuation and withdrawal
Indication: Angiogenesis disorder; colorectal tumor; Kaposi’s sarcoma; lung tumor; melanoma; myeloid leukemia; myeloproliferative disorder;
neoplasm; solid tumor
Action: Angiogenesis inhibitor; protein tyrosine kinase (PTK) inhibitor; MAP kinase (MAPK) inhibitor; VEGF antagonist
Synonyms: Flk-1/KDR RTK antagonists; SU-5416; angiogenesis inhibitors; Semaxanib
Table 2 Developmental history.
Developer Country Status Indication Date
Sugen Inc. USA DR Neoplasm 09-Nov-95
Sugen Inc. USA DR Angiogenesis disorder 09-Nov-95
Taiho Pharmaceutical Co. Ltd. Japan DR Neoplasm 09-Nov-95
Sugen Inc. USA C1 Solid tumor 01-Oct-97
Sugen Inc. USA C2 Kaposi’s sarcoma 21-Sep-98
Taiho Pharmaceutical Co. Ltd. Japan C1 Solid tumor 13-Nov-98
Taiho Pharmaceutical Co. Ltd. Japan C2 Kaposi’s sarcoma 21-Sep-98
Sugen Inc. USA C1 Myeloproliferative disorder 17-Nov-98
Sugen Inc. USA C3 Colorectal tumor 01-May-99
Sugen Inc. USA C3 Lung tumor 01-May-99
Sugen Inc. Western Europe C2 Kaposi’s sarcoma 29-Sep-99
Sugen Inc. USA C2 Myeloid leukemia 01-Dec-00
Sugen Inc. USA DR Melanoma 29-May-01
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among concurrent biological therapy with bevacizumab,
cetuximab, or both.
The success of bevacizumab and VEGF targeting has stim-
ulated other strategies to block new blood vessel growth in tu-
mors. The precise mechanism by which bevacizumab improves
cancer chemotherapy in colorectal is not precisely known.
Originally, such strategies were designed to ‘‘starve’’ the tumor
by blocking its blood supply; however, bevacizumab is most
effective in combination with blood-borne chemotherapy and
it has relatively modest activity as single agents.
One alternative hypothesis is that VEGF targeting actually
normalizes tumor vasculature and enhances drug delivery to
the growing tumor cells. Nonetheless, this lack of a complete
mechanistic understanding of VEGF-directed therapy has
not deterred other anti-angiogenic strategies from entering
clinical development. One novel strategy has targeted a large
and diverse family of cell adhesion proteins called integrins.
These are a complex superfamily of transmembrane glycopro-
teins that exist as heterodimers composed of a and b chains.
Different heterodimers have different speciﬁcities of ligand
binding and are associated with a variety of functions in a
broad range of tissues. There are 18 known a integrin subunits
and 8 b subunits, which associate to form at least 24 heterodi-
meric a/b pairs. Integrins have dual functions, serving as cell-
surface adhesion structural proteins and as signaling receptors,
although unlike receptor tyrosine kinases, they have no intrin-
sic enzyme activity. Integrins mediate cell–extracellular matrix
and cell–cell interactions. Certain integrins can stimulate endo-
thelial and tumor cell survival, whereas others promote cell
aggregation and can regulate cell trafﬁcking functions. They
are postulated to have major but complex roles in tumor angi-
ogenesis, invasion, and metastases. Some integrin subfamilies
are functionally interrelated to signaling via the PI3 K/Aktpathway in some systems such as hormone resistant prostate
cancer cells. The various integrin heterodimers have different
ligand-binding speciﬁcities. For example, the ﬁbronectin pro-
tein binds to a4b1 and a5b1 integrins, whereas lamin and col-
lagen bind to a3b1, a2b1, and a1b1 integrins.
A number of integrin-targeting agents have entered clinical
trials. One such agent is M200 (volociximab), a chimeric IgG4
anti-a5b1 antibody being developed by Protein Design Labora-
tories, Inc. The a5b1 integrin is involved in cell adhesion,
migration, and enhanced cell survival. It is present on tumor
endothelial cells and it helps to regulate growth factor-activated
endothelial cells. The a5b1 integrin is also present on some
tumor cells and on monocytes; however, it is not seen in endo-
thelial cells from normal blood vessels. Inhibition of a5b1
ﬁbronectin binding leads to apoptosis of activated endothelial
cells, inhibition of cell migration, and prevention of tumor-
associated neoangiogenesis. The M200 antibody blocks
binding of a5b1 to ﬁbronectin and it can inhibit tumor endo-
thelial cell a5b1-mediated angiogenesis. In laboratory studies
it can inhibit human endothelial cell tube formation and it
blocks choroidal neo-vascularization in primate models. It also
actively blocks blood vessel growth in xenografts in chicken
chorioallantoic membrane (CAM) assays. M200 cross reacts
with chicken and primate a5b1 but not with rodent integrins,
making it inactive in standard rodent-based models. In a Phase
I study of intravenously administered M200 infused over 1 h
weekly, it was well tolerated with no serious dose-limiting ad-
verse events. Pharmacokinetics were non-dose proportional
with decreased clearance seen at higher dose levels consistent
with possible saturation tissue kinetics. The overall plasma
half-life was approx. 16 days. In the ﬁrst six evaluated patients,
a partial response was observed in a patient with renal cell
cancer and prolonged stable disease lasting longer than
4 months was seen in patients with non-small cell lung cancer,
Table 3 Literature classiﬁcations.
Study type Eﬀect studied Experimental model Result
Biology
In vitro/in vivo Development of a strategy to
combat ophthalmic diseases
with
angiogenesis
Retinal cultures, explants
and in vivo
eye model
Analysis of angiogenesis inhibitors
for the treatment of ophthalmic neo-vascular diseases,
such as age-related
macular degeneration and diabetic retinopathy
Computational
chemistry
Screening for a novel class of
broadly applicable drug
candidates for the inhibition
of RTKs
Computational chemistry The solution of the three-dimensional
co-crystal structure of FGF RTK
with two of Sugen’s TK inhibitors
In vitro/in vivo Tyrosine kinase inhibition,
proliferation indexes
endothelium tumor growth
Receptor phosphorylation in3T3
cells 3H-thymidine
uptake by EC, tumor growth of
A375,
A431, Calu-6 C6, LNCAP, PH4-
VEGF, 3T3HER2, 488G2m2,
SF763T, and SF67T
IC50 = 1.04 lM, 100-fold less than
other TRKs. Reduced 3H uptake. Reduced growth of
tumors except for SF763T and SF67T
Synthesis
chemistry
Synthesis and biological
evaluation of RTK inhibitors
Synthesis chemistry 3-Subsituted indolin-2-ones exhibited selectivity
toward particular RTKs
In vitro Assessment of SU-5416
selectivity against Flk-1/
KDR
kinase
Human endothelial cells SU-5416 was reported as a potent and selective Flk-1/
KDR kinase inhibitor, which blockaded receptor
auto-phosphorylation, endothelial cell mitogenesis,
tumor growth, angiogenesis and micro-hemodynamics
In vitro/in vivo Assessment of SU-5416
potency against a broader
range of RTK
kinases
HUVECs and mice
transplant
The derivative 3,5-dimethyl pyrrole-analog was found
to be the superior compound, with an IC50 = 40 nM.
SU-5416 was also highly selective for
Flk-1/KDR, being essentially inactive at other RTKs.
This compound dramatically inhibited tumor size and
neo-vascularization with a broader
anti-tumor spectrum: i.p.
administration blockaded eight out of
ten diﬀerent cell lines grown subcutaneously.
Although the plasma
half-life was short (30 min), the half-
life for activity against Flk-1 was
about 20 h, ostensibly due to the lipophilicity of the
compound
In vivo Assessment of subcutaneous
tumor growth of cells derived
from various tissues
Mice Systemic administration of SU-5416
at non-toxic doses (25 mg/kg/day) resulted in the
inhibition of subcutaneous tumor growth of cells
derived from various tissue origins.
The anti-tumor eﬀect of SU-5416 was accompanied by
the appearance of
pale white tumors that were resected
from drug-treated animals
In vitro/in vivo Evaluation of the
biochemical and biological
functions of SU-
5416 and other RTK
inhibitors
C-KIT SU-5416 and SU-6668 inhibited the biochemical and
biological functions
of C-KIT (IC50 = 0.1–1 lM)
In vivo Evaluation of SU-5416
possible
inhibition of Flt-1 receptor
Mice and rats SU-5416 inhibited the TK VEGF receptor, Flt-1. SU-
5416 and SU-6668
exhibited comparative diﬀerences in toxicity proﬁle
following intravenous
administration
Metabolism
In vitro Analysis of VEGF-
stimulated
thymidine uptake
Cultured human endothelial cells
(HUVECs)
SU-5416 inhibited VEGF-stimulated thymidine
uptake at 0.1 lM,
whereas FGF-1-mediated thymidine uptake was
inhibited only at a
concentration of 10 lM
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Table 3 (continued)
Study type Eﬀect studied Experimental model Result
In vivo Determination of toxicity
metabolism and elimination
Patients with advanced
malignances
SU-5416 in a dose-escalating trial exhibited mild
toxicity, and the elimination t½ was approximately
50 min
In vivo Assessment of SU-5416 half-
life
and prolonged eﬀects
Mice and human tumor
xenograft models
SU-5416 exhibited a short plasma half-life, but
prolonged in vivo eﬀects. This compound inhibited
VEGF-dependent KDR phosphorylation by
blockading subcellular localization
In vitro/in vivo To investigate the
metabolism
of SU-5416 and its major
metabolites by HPLC
Mouse, rat, dog, monkey
and human liver microsomes
Microsomes, incubated with SU-5416 (25 lM) in the
presence of NADPH-generating system, showed the
compound’s conversion to at least 6 polar metabolites,
where the overall rate of metabolism followed the rank
monkeyPmouse rat > dog > human
In vivo The eﬀect of a combination
of
SU-5416 and ﬂuorouracil/
leucovorin on the
progression
of colon cancer
Patients with untreated
metastatic colon cancer
SU-5416 (85 or 145 mg/m2) exhibited as response rate
of 36% with as time to progression of 9 months, a time
to failure of 8.5 months and a median survival time of
22.5 months
Clinical
Initiation of clinical trials
with
Flk-1 TK angiogenesis
inhibitors
Patients with solid tumor cancers The safety and eﬃcacy of the company’s lead compound,
SU-5416, were established
Initiation of phase I
angiogenesis
inhibitor study
Patients with solid tumors and
tumor metastasis
The initiation of this study represented the ﬁrst
time a small-molecule inhibitor targeting the
angiogenic mechanism has been administered in
humans. This was carried out to assess the safety and
dosage range of SU-5416, which was
administered intravenously on a twice-weekly schedule.
SU-5416 has been well tolerated at a
dose of 4.4 to 65 mg/m2. The drug exhibited only mild
toxicity, and the elimination t½ was
approximately 50 min. In four out of ﬁve patients
experiencing tumor stabilization, a decrease in
tumor permeability and leakiness was demonstrated
Initiation of phase I/II
clinical trial in Kaposi’s
sarcoma
Patients (n= 30) with AIDS-
related Kaposi’s sarcoma
The study endpoints, carried out at ﬁve US
medical centers specializing in AIDS-related
malignancies, included measurement of objective
response and time-to-disease progression
in addition to safety and pharmacokinetic parameters
Initiation of registrational
studies with SU-5416
Patients with Kaposi’s sarcoma,
colorectal and basal cell cancer
Of the patients who remained in the study
evaluating various doses, the majority exhibited
well tolerance with mild negative repercussion.
Expected side eﬀects included nausea, vomiting,
headache and transient increase in liver
transaminases. Most patients showed stable
disease for a prolonged period of time
Initiation of multiple phase
II and I/II studies
Patients with solid tumors
(including renal,
head and neck, sarcoma, and
prostate cancers)
(n= 500–700) in approximately
20 leading cancer
centers in the USA
The trials planned to test SU-5416 as either a
single agent or in combination with other drugs in
a variety of cancer indications
Entrance of SU-5416 into
phase II/III trials
Patients with AIDS-related
Kaposi’s sarcoma,
colorectal and non-small cell lung
cancer
The study oﬀered multiple information of the drug’s
potency, safety and eﬃcacy
(continued on next page)
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Phase II trial in combination
with paclitaxel
Patients with angiosarcoma and
cervical cancer
SU-5416 in combination with standard-dose paclitaxel
(175 mg/m2, q3w) showed the regimen is tolerated, with no
eﬀect on paclitaxel pharmacokinetics
Phase I/II study in
combination
with 5-ﬂuorouracil
and leucovorin
Patients with metastatic
colorectal cancer
Patients were found to be free of tumor growth and spread
for a median time of 9.2 months
120 J.J. Haddadmelanoma, and parotid cancers. No disease stabilization was
seen in the four patients with colon cancer enrolled in this study.
Currently, M200 is in phase II studies in renal cell cancer.
Eisai Pharmaceuticals has adopted a strategy of using
small-molecule inhibitors of integrins in the development of
E7820, a novel oral sulfonamide agent that reduces the expres-
sion of a2, a3, a5, and b1 mRNA in tumor tissues. E7820
blocks VEGF- and bFGF-induced human umbilical vascular
endothelial cell tube formation in laboratory experiments
and it effectively inhibits the growth of human breast and pan-
creas cancer xenografts. In a phase I study of daily oral E7820,
the agent was well tolerated with dose-proportional pharmaco-
kinetics. Major dose-limiting toxicities consisted of grade 3
thrombocytopenia and elevation of hepatic transaminases.
Prolonged disease stabilization lasting longer than 6 months
was noted in four total patients, two with colorectal cancer
and one with bladder cancer and malignant melanoma. Cur-
rent studies are examining E7820 in combination with irinotec-
an, cetuximab, and other targeted therapies. In preclinical
in vitro and in vivo data, marked synergy was observed when
E7820 was combined with the other chemotherapeutic and tar-
geted agents.
‘‘Other integrin-targeting agents in clinical development in-
clude MEDI522 (Vitaxin) a humanized IgG1 anti-avb3 anti-
body developed by MedImmune. It is in phase II trials against
melanoma, prostate, leiomyosarcoma, and colorectal cancer.
Cilengitide (EMD121974) is a cycle peptide inhibitor of avb3
and avb5 developed by Merck KGaA. This agent is in phase
II studies in gliomas, melanoma, and prostate cancers. Finally,
CNTO 95 is a fully human IgG1 anti-avb3 and anti-avb5 anti-
body that is being developed by Medarex/Centocor. Thus, this
remains an active area of clinical development.’’
13. Conclusion and prospects
Currently, much of the pharmaceutical industry’s resources are
geared toward developing drugs that mimic the effects of cetux-
imab or bevacizumab in hitting these same targets to try to de-
velop better and more effective therapies. Although advances
and reﬁnements in our current treatments will undoubtedly
arise from these efforts, a larger question is what new molecular
targets will be important for the development of future targeted
therapies. For the purposes of the aforementioned discussion, I
wish to speculate as to what types of agents and targets will
yield the next generation of therapies for cancer. There is no
absolute way to be precise in these predictions, any more than
a venture capitalist can reliably pick a winner in the stock mar-
ket. However, it is possible to make some highly educated
guesses (Saltz, 2007). The pathways and the inherent targets
discussed here reﬂect our personal biases and are inﬂuenced
by our own direct experience in cancer drug development.Thus, it is likely that when this manuscript is reviewed in 5 or
10 years, its likelihood of being highly accurate is small. None-
theless, it is both exciting and exhilarating to consider select
areas of applied scientiﬁc research with the highest potential
for yielding the next generation of clinical advances in cancer
therapeutics. I certainly have great conﬁdence that the current
ongoing basic research in cancer biology ultimately will lead to
tomorrow’s great therapeutic advances (Tables 1–3).Acknowledgments
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